Kozak RW[au] - Search Results

Year	Number of Results
1981	1
1982	1
1985	1
1986	2
1987	3
1988	1
1989	2
1990	2
1992	5
1993	1
1994	1
1996	2
1999	1
2024	0

1

Zoon KC, zur Nedden DL, Kozak RW, Gurari-Rotman D. Zoon KC, et al. Among authors: kozak rw. J Pharm Biomed Anal. 1989;7(2):147-54. doi: 10.1016/0731-7085(89)80078-0. J Pharm Biomed Anal. 1989. PMID: 2488615 Review.

2

The autologous mixed-lymphocyte reaction.

Weksler ME, Moody CE Jr, Kozak RW. Weksler ME, et al. Among authors: kozak rw. Adv Immunol. 1981;31:271-312. doi: 10.1016/s0065-2776(08)60923-2. Adv Immunol. 1981. PMID: 6459011 Review. No abstract available.

3

Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy.

Kozak RW, Atcher RW, Gansow OA, Friedman AM, Hines JJ, Waldmann TA. Kozak RW, et al. Proc Natl Acad Sci U S A. 1986 Jan;83(2):474-8. doi: 10.1073/pnas.83.2.474. Proc Natl Acad Sci U S A. 1986. PMID: 3079913 Free PMC article.

4

IL-2 receptors in adult T-cell leukemia: a target for immunotherapy.

Waldmann TA, Kozak RW, Tsudo M, Oh-ishi T, Bongiovanni KF, Goldman CK. Waldmann TA, et al. Among authors: kozak rw. Haematol Blood Transfus. 1987;31:110-5. doi: 10.1007/978-3-642-72624-8_23. Haematol Blood Transfus. 1987. PMID: 3127278 Review. No abstract available.

5

Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.

Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, Garmestani K, Brechbiel MW, Curcio MJ, Pippin CG, Tiffany-Jones L, Geerlings MW Sr, Apostolidis C, Molinet R, Geerlings MW Jr, Gansow OA, Scheinberg DA. Nikula TK, et al. Among authors: kozak rw. J Nucl Med. 1999 Jan;40(1):166-76. J Nucl Med. 1999. PMID: 9935073 Free article.

6

Interleukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor.

Lorberboum-Galski H, Kozak RW, Waldmann TA, Bailon P, FitzGerald DJ, Pastan I. Lorberboum-Galski H, et al. Among authors: kozak rw. J Biol Chem. 1988 Dec 15;263(35):18650-6. J Biol Chem. 1988. PMID: 3143716 Free article.

7

In vitro and in vivo suppression of interleukin-2-activated killer cell activity by chimeric proteins between interleukin-2 and Pseudomonas exotoxin.

Puri RK, FitzGerald D, Leland P, Kozak RW, Pastan I. Puri RK, et al. Among authors: kozak rw. Cell Immunol. 1992 Sep;143(2):324-34. doi: 10.1016/0008-8749(92)90029-o. Cell Immunol. 1992. PMID: 1511480

8

Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia.

Kreitman RJ, Chaudhary VK, Kozak RW, FitzGerald DJ, Waldman TA, Pastan I. Kreitman RJ, et al. Among authors: kozak rw. Blood. 1992 Nov 1;80(9):2344-52. Blood. 1992. PMID: 1421405 Free article.

9

Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.

Tsudo M, Kozak RW, Goldman CK, Waldmann TA. Tsudo M, et al. Among authors: kozak rw. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9694-8. doi: 10.1073/pnas.83.24.9694. Proc Natl Acad Sci U S A. 1986. PMID: 3099289 Free PMC article.

10

Regulatory considerations when developing biological products. Report of the Center for Biologics Evaluation and Research.

Kozak RW, Durfor CN, Scribner CL. Kozak RW, et al. Cytotechnology. 1992;9(1-3):203-10. doi: 10.1007/BF02521747. Cytotechnology. 1992. PMID: 1369172

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

23 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year